The team's ongoing experiments focus on in vivo IN administration and IV injection PET imaging of [68Ga]-NOTA-insulin in non-human primate models of Alzheimer's disease, the determination of metabolic plasma-blood parameters, and the correlation of radiotracer uptake with Aβ42 and tau levels. Here, INS is linked to early-onset autosomal dominant Alzheimer disease.